In the press

Virica has been selected as a project lead for one of NIIMBL | The National Institute for Innovation in Manufacturing Biopharmaceuticals planned projects, which aim to address key opportunities for innovation in biopharmaceutical manufacturing. NIIMBL is a public-private partnership whose mission is to accelerate biopharmaceutical manufacturing. Virica, with support from NIIMBL members AstraZeneca and Sartorius Stedim Biotech, aims to increase [...]

Navigating the fast-paced cell and gene therapy landscape? Stay ahead of the curve with our curated news on viral vectors in cell & gene therapy April 2024 edition. Read here: Virica's Industry Insights- April Edition.  

Navigating the fast-paced cell and gene therapy landscape? Stay ahead of the curve with our curated news on viral vectors in cell & gene therapy January edition. Read here: Virica's Industry Insights- January Edition  

Our own Ella Korets-Smith, Chief Strategy Officer and co-founder of Virica Biotech, has been featured in the Ottawa Business Journal for her impactful role in advancing breakthrough biotechnology to “democratize gene therapy.” Virica’s vision is to make gene therapies accessible and affordable. Ella shares her entrepreneurial journey building Virica from an idea to a thriving [...]

Virica Biotech Inc. (“Virica”), a leading developer of cell enhancers for scaling of viral vectors and cell and gene therapies, announces a significant expansion of bioprocessing services through a strategic partnership with Carleton University in a PRESS RELEASE. "This multi-year, multi-million-dollar research and infrastructure partnership will help drive innovation and talent development in the Ottawa [...]

Cell & gene therapy (C&GT) is complex, expensive and lacks standardization. How do you effectively evaluate and make informed decisions to identify a winning viral vector production strategy to improve the accessibility & affordability of C&GT? We are thrilled to announce our Fast Facts video with Cell & Gene Insights, where our expert Andrea Vervoort, [...]

Virica Biotech Inc. (“Virica”), a leading developer of cell enhancers for scaling of viral vectors, as well as cell and gene therapies, announced today the expansion of their sales team along with a full presentation calendar in a PRESS RELEASE.  Azra Benson, a veteran stem cell scientist with extensive commercial experience in the cell and [...]

Closing the gap: Modeling benefits of AAV scale-up using novel enhancers In partnership with Cell and Gene Insights, Virica will present on the benefits of viral sensitizers and show how bioprocessing modeling can be used to inform decisions related to scaling up or scaling out processes. Presenters will include; Dr. Jean-Simon Diallo (CEO Virica [...]

Innate cellular antiviral defences present a significant challenge to viral vector production and transduction for cell and gene therapy manufacturing. Learn about what they are, the challenges they pose and Virica's solution to mitigating its impact on viral vector yield and quality. View infographic here: Antiviral Defenses: What You Need to Know       [...]

Navigating the fast-paced cell and gene therapy landscape? Stay ahead of the curve with our curated news on viral vectors in cell & gene therapy October edition. Read here: Virica's Industry Insights- October Edition